Drug-induced uveitis related to Checkpoint inhibitors and MAPkinase inhibitors.

HOME
>
論文・技術情報
>
Drug-induced uveitis related to Checkpoint inhibitors and MAPkinase inhibitors.

Drug-induced uveitis related to Checkpoint inhibitors and MAPkinase inhibitors.

アブストラクト	We classified drug-induced uveitis related to Immune Checkpoint inhibitors (ICIs) and MAP-kinase pathway inhibitors (MAPKi), including BRAF-inhibitors (BRAFi) and MEK-inhibitors (MEKi), according ophthalmological examination. Cases were retrieved from the French pharmacovigilance database (FPVD) which included all adverse drug reactions (ADR) registred by the French Regional Pharmacovigilance Network. We collected 113 cases of drug-induced uveitis (46 ICI-related and 67 MAPKi-related). The classification analysis identified four clusters. ICI were associated with anterior, posterior and panuveitis with severe manifestations such as retinal vasculitis and optic neuropathy. BRAFi were associated with anterior and panuveitis. MEKi inhibitors were associated with early serous-retinal detachment.
ジャーナル名	Ophthalmology
Pubmed追加日	2023/10/12
投稿者	Thibault, Thomas; Ben Ghezala, Ines; Freppel, Romane; Rajillah, Abdessamad; Boulay, Charlene; Brunel, Pierre; Atzenhoffer, Marina; Auvens, Clement; Devilliers, Herve; Grandvuillemin, Aurelie
組織名	Internal Medicine and Systemic Diseases Unit, University Hospital Dijon-Burgundy,;Dijon, France; Centre regional de pharmacovigilance de Bourgogne, University;Hospital Dijon-Burgundy, Dijon, France; INSERM CIC-EC 1432, Clinical;Investigation Center, University Hospital Dijon-Burgundy, Dijon, France.;Electronic address: thomas.thibault@chu-dijon.fr.;Ophthalmology Department, University Hospital, University Hospital;Dijon-Burgundy, Dijon, France; INSERM, CIC 1432, Clinical Investigation Center,;Clinical Epidemiology/Clinical Trials Unit, University Hospital Dijon-Burgundy,;Dijon, France.;Centre regional de pharmacovigilance de Bourgogne, University Hospital;Dijon-Burgundy, Dijon, France.;Regional Centre of Pharmacovigilance and Pharmacoepidemiology, CHU de Rouen,;Rouen, Normandie, France.;Department of Pharmacy, CHU de Saint-Etienne, Saint-Etienne,;Auvergne-Rhone-Alpes, France.;Service Hospitalo-Universitaire de Pharmaco-Toxicologie, Hospices Civils de Lyon,;Lyon, Auvergne-Rhone-Alpes, France.;Dijon, France; INSERM CIC-EC 1432, Clinical Investigation Center, University;Hospital Dijon-Burgundy, Dijon, France.
Pubmed リンク	https://www.ncbi.nlm.nih.gov/pubmed/37820932/